Skip to main
CATX
CATX logo

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc. is positioned favorably in the radiopharmaceutical market due to its innovative lead-212 based therapies, which demonstrate superior cancer cell killing potential and a favorable safety profile through targeted alpha radiation. Recent industry developments, such as significant investments in isotope production, indicate a growing interest in the radiopharmaceutical sector, potentially enhancing supply dynamics and market opportunities. Favorable clinical data for its flagship product VMT-α-NET, showing improved response rates compared to existing therapies, supports a positive outlook for the company's future performance as they advance their pipeline programs.

Bears say

Perspective Therapeutics Inc faces substantial commercialization and pricing risks, primarily due to the competitive landscape and potential inadequacies in delivering superior products. The company also encounters significant operational challenges evidenced by negative clinical outcomes with its lead asset and delays in advancing its pipeline candidates, which could hinder regulatory approval. Additionally, the ongoing supply shortages faced by competitors coupled with the company's reliance on the performance of its proprietary technology may further exacerbate its risk profile and negatively impact its financial health.

CATX has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Buy based on their latest research and market trends.

According to 9 analysts, CATX has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.